Previous 10 | Next 10 |
Fourth quarter net sales of $117.6 million, within 3% of our 2019 results US Spine implant sales grew 11% compared to fourth quarter 2019, driven by record M6-C artificial cervical disc performance Strong cash flow performance in the quarter, free cash flow...
Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company with a spine and extremities focus, today announced that President and Chief Executive Officer Jon Serbousek and Chief Financial Officer Doug Rice will participate in a fireside chat during the BTIG MedTech, Digital He...
Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company with a spine and extremities focus, today announced that it plans to release financial results for the fourth quarter and full year 2020 before market open on Friday, February 26, 2021. Jon Serbousek, President and Chi...
Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company with a spine and extremities focus, today announced the U.S. and European full market launch of the FITBONE ® intramedullary lengthening system for limb lengthening and deformity correction of the femur an...
Orthofix Medical (OFIX) announces publication of the full two-year data from its U.S. Investigational Device Exemption ((IDE)) study of the M6-C artificial cervical disc. Published in The Spine Journal, the study results show that M6-C disc was safe, effective and non-inferior to an...
Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company with a spine and extremities focus, today announced the publication of the full two-year data from its U.S. Investigational Device Exemption (IDE) study of the M6-C ™ artificial cervical disc. This press...
The following slide deck was published by Orthofix Medical Inc. in conjunction with this event. For further details see: Orthofix Medical (OFIX) Investor Presentation - Slideshow
For Q4, Orthofix Medical (OFIX) provided prelim net sales of ~$118M (-3% Y/Y, +6% Q/Q); FY20 sales are expected at $407M (-12% Y/Y).Analysts consensus estimate Q4 net sales at $110.02M while FY20 net sales are seen at $398.98M.U.S. Spinal Implants Q4 net sales increased 11% Y/Y; Motion P...
Fourth quarter net sales of approximately $118 million, an increase of 6% sequentially and a decrease of 3% versus the prior year U.S. Spinal Implants fourth quarter net sales increased 11% over the prior year Motion Preservation fourth quarter net sales in...
Orthofix Medical Inc. (NASDAQ:OFIX) today announced that President and Chief Executive Officer Jon Serbousek and Chief Financial Officer Doug Rice will participate in two upcoming virtual investor conferences. J.P. Morgan Healthcare Conference The Company will be presenting on...
News, Short Squeeze, Breakout and More Instantly...
Orthofix Medical Inc. Company Name:
OFIX Stock Symbol:
NASDAQ Market:
Orthofix Medical Inc. Website:
Wednesday, August 14, 2024 at 2:30 pm Eastern Time Orthofix Medical Inc . (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced that the Company will participate in Canaccord Genuity's 44th Annual Growth Conference in Boston. Management is scheduled to pre...
Orthofix Medical Inc . (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced the appointment of Stephanie Walsh as Chief Human Resources Officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240716004...
Orthofix Medical Inc . (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced the 510(k) clearance and first U.S. implant of the Fitbone ™ Transport and Lengthening System. Used to treat large bone defects in the femur and tibia due to trauma, infectious or ma...